PayPoint plc : Director/PDMR Shareholding
15 October 2026
PayPoint Plc
(the "Company")
Notification of a transaction by a Director / Person Discharging Managerial Responsibilities (“PDMR”)
The Company has been notified that on 14 October 2026, Rob Harding, Chief Financial Officer, acquired 49 ordinary shares of 0.3611 pence each in the Company (‘Ordinary Shares’) at a price of £6.907933 per share and 16 Ordinary Shares at a price of £6.9040 per share, as a result of his participation in a third-party Dividend Reinvestment Plan.
The Notification of Dealing Form can be found below.
This Notification is made in accordance with the requirements of the UK Market Abuse Regulation.
Enquiries:
PayPoint Plc
Sophie Line, on behalf of Indigo Corporate Secretary Limited, Company Secretary
+44 (0)7927132060
Steve O'Neill, Chief Marketing and Corporate Affairs Officer
+44 (0)7919488066
LEI: 5493004YKWI8U0GDD138
https://www.paypointbusiness.com/corporate
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Rob Harding |
| 2. | Reason for the notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | PayPoint Plc |
| b) | LEI | 5493004YKWI8U0GDD138 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 0.3611 pence each ISIN: GB00BVMTNR93 |
| b) | Nature of the transaction | Acquisition of ordinary shares of 0.3611 pence each through a third-party Dividend Reinvestment Plan |
| c) | Price(s) and volume(s) |
|
| d) | Aggregated information |
|
| e) | Date of the transaction | 14 October 2026 |
| f) | Place of the transaction | London Stock Exchange, Main Market (XLON) |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Childfree Trust Named One of TIME’s Best Inventions of 2026
- Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
- Arbitrum Price Prediction Through 2030: ARB’s Long-Term Bet Meets Remittix’s Near-Term November Launch Catalyst
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share